376 related articles for article (PubMed ID: 29461566)
21. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
22. Updates on cardiovascular outcome trials in diabetes.
Schnell O; Rydén L; Standl E; Ceriello A;
Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
[TBL] [Abstract][Full Text] [Related]
23. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
[TBL] [Abstract][Full Text] [Related]
24. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Niessner A; Tamargo J; Koller L; Saely CH; Schmidt TA; Savarese G; Wassmann S; Rosano G; Ceconi C; Torp-Pedersen C; Kaski JC; Kjeldsen KP; Agewall S; Walther T; Drexel H; Lewis BS
Eur Heart J; 2018 Jun; 39(24):2274-2281. PubMed ID: 29126266
[No Abstract] [Full Text] [Related]
25. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
Lamos EM; Hedrington M; Davis SN
Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
[TBL] [Abstract][Full Text] [Related]
26. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
[TBL] [Abstract][Full Text] [Related]
27. Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol.
Butterly E; Wei L; Adler AI; Almazam SAM; Alsallumi K; Blackbourn LAK; Dias S; Hanlon P; Hughes K; Lewsey J; Lindsay R; McGurnaghan S; Petrie J; Phillippo D; Sattar N; Tomlinson LA; Welton N; Wild S; McAllister D
BMJ Open; 2022 Oct; 12(10):e066491. PubMed ID: 36302574
[TBL] [Abstract][Full Text] [Related]
28. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile.
Muzurović E; Mikhailidis DP
Expert Opin Pharmacother; 2020 Dec; 21(17):2125-2135. PubMed ID: 32697112
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract][Full Text] [Related]
30. DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease.
Sonoda K; Saguil A
Am Fam Physician; 2022 Jul; 106(1):24-25. PubMed ID: 35839371
[No Abstract] [Full Text] [Related]
31. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
Lim S; Kim KM; Nauck MA
Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
[TBL] [Abstract][Full Text] [Related]
32. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
Fattah H; Vallon V
Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
[TBL] [Abstract][Full Text] [Related]
33. How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Sukkar L; Young T; Jardine MJ
Kidney Blood Press Res; 2020; 45(6):823-836. PubMed ID: 33271545
[TBL] [Abstract][Full Text] [Related]
34. Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States.
Al-Kindi SG; Janus SE; Neeland IJ; Rajagopalan S
J Diabetes Complications; 2022 Jul; 36(7):108224. PubMed ID: 35667964
[No Abstract] [Full Text] [Related]
35. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
36. New Agents for the Treatment of Type 2 Diabetes.
Libianto R; Ekinci EI
Crit Care Clin; 2019 Apr; 35(2):315-328. PubMed ID: 30784612
[TBL] [Abstract][Full Text] [Related]
37. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes.
Cattadori G; Pantanetti P; Ambrosio G
Diabetes Res Clin Pract; 2019 Nov; 157():107835. PubMed ID: 31479706
[TBL] [Abstract][Full Text] [Related]
38. Glucose-Lowering Medications and Cardiovascular Outcomes.
Shanmugasundaram M; Pineda JRE; Murugapandian S
Curr Cardiol Rep; 2021 Mar; 23(4):24. PubMed ID: 33655453
[TBL] [Abstract][Full Text] [Related]
39. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.
Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
Lancet Diabetes Endocrinol; 2021 Dec; 9(12):825-836. PubMed ID: 34656210
[TBL] [Abstract][Full Text] [Related]
40. Safety and cardiometabolic efficacy of novel antidiabetic drugs.
Michaud L; Seplowe M; Meir J; Aronow WS
Expert Opin Drug Saf; 2023 Feb; 22(2):119-124. PubMed ID: 36877138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
